Do immune checkpoint inhibitors need new studies methodology?

Roberto Ferrara, Sara Pilotto, Mario Caccese, Giulia Grizzi, Isabella Sperduti, Diana Giannarelli, Michele Milella, Benjamin Besse, Giampaolo Tortora, Emilio Bria

Research output: Contribution to journalReview article

Abstract

Immune checkpoint inhibitors (ICI) have widely reshaped the treatment paradigm of advanced cancer patients. Although multiple studies are currently evaluating these drugs as monotherapies or in combination, the choice of the most accurate statistical methods, endpoints and clinical trial designs to estimate the benefit of ICI remains an unsolved methodological issue. Considering the unconventional patterns of response or progression [i.e., pseudoprogression, hyperprogression (HPD)] observed with ICI, the application in clinical trials of novel response assessment tools (i.e., iRECIST) able to capture delayed benefit of immunotherapies and/or to quantify tumor dynamics and kinetics over time is an unmet clinical need. In addition, the proportional hazard model and the conventional measures of survival [i.e., median overall or progression free survival (PFS) and hazard ratios (HR)] might usually result inadequate in the estimation of the long-term benefit observed with ICI. For this reason, innovative methodologies such as milestone analysis, restricted mean survival time (RMST), parametric models (i.e., Weibull distribution, weighted log rank test), should be systematically investigated in clinical trials in order to adequately quantify the fraction of patients who are "cured", represented by the tails of the survival curves. Regarding predictive biomarkers, in particular PD-L1 expression, the integration and harmonization of the existing assays are urgently needed to provide clinicians with reliable diagnostic tests and to improve patient selection for immunotherapy. Finally, developing original and high-quality study designs, such as adaptive or basket biomarker enriched clinical trials, included in large collaborative platforms with multiple active sites and cross-sector collaboration, represents the successful strategy to optimally assess the benefit of ICI in the next future.

Original languageEnglish
Pages (from-to)S1564-S1580
JournalJournal of Thoracic Disease
Volume10
DOIs
Publication statusPublished - May 1 2018

Keywords

  • Clinical trial design
  • Immune checkpoint inhibitors (ICI)
  • Long-term benefit
  • Milestone
  • Survival analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Do immune checkpoint inhibitors need new studies methodology?'. Together they form a unique fingerprint.

Cite this